| Title |
Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
|
|---|---|
| Published in |
OncoTargets and therapy, February 2017
|
| DOI | 10.2147/ott.s102646 |
| Pubmed ID | |
| Authors |
Henriette Huber, Simone Edenhofer, Sven Estenfelder, Stephan Stilgenbauer |
| Abstract |
Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies are presently being introduced and represent a considerable breakthrough concerning effectiveness and safety profile. In particular, the very high-risk group of CLL patients, defined by the genetic aberration del(17p) and/or TP53 mutation, benefit from the new agents. These genetic abnormalities are the most relevant negative prognostic markers in the context of chemoimmunotherapy. New targeted therapies allow different approaches to improve outcomes. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 19% |
| Student > Master | 4 | 13% |
| Student > Doctoral Student | 3 | 10% |
| Researcher | 3 | 10% |
| Lecturer | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 10 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 35% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Nursing and Health Professions | 2 | 6% |
| Chemical Engineering | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 9 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2022.
All research outputs
#7,208,166
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#365
of 3,016 outputs
Outputs of similar age
#126,406
of 424,972 outputs
Outputs of similar age from OncoTargets and therapy
#14
of 77 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,972 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.